Details of the BTS

General Information of Binding Target of SBP (BTS) (ID: ST00057)
BTS Name
Glutamate carboxypeptidase 2
Synonyms
EC 3.4.17.21; Cell growth-inhibiting gene 27 protein; Folate hydrolase 1; Folylpoly-gamma-glutamate carboxypeptidase; FGCP; Glutamate carboxypeptidase II; GCPII; Membrane glutamate carboxypeptidase; mGCP; N-acetylated-alpha-linked acidic dipeptidase I; NAALADase I; Prostate-specific membrane antigen; PSM; PSMA; Pteroylpoly-gamma-glutamate carboxypeptidase
BTS Type
Protein
Family
Peptidase M28 family;
M28B subfamily
Gene Name
FOLH1
Organism
Homo sapiens (Human)
Function
Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. In the intestine, required for the uptake of folate. In the brain, modulates excitatory neurotransmission through the hydrolysis of the neuropeptide, N-aceylaspartylglutamate (NAAG), thereby releasing glutamate. Involved in prostate tumor progression.; Also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC.
UniProt ID
Q04609
UniProt Entry
FOLH1_HUMAN
PFam
PF02225 ; PF04389 ; PF04253
Gene ID
2346
Sequence
MWNLLHETDSAVATARRPRWLCAGALVLAGGFFLLGFLFGWFIKSSNEATNITPKHNMKA
FLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYP
NKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYA
RTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVK
SYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYY
DAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIG
TLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFAS
WDAEEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKE
LKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKN
WETNKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDY
AVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIV
LRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVD
PSKAWGEVKRQIYVAAFTVQAAAETLSEVA
Sequence Length
750
Synthetic Binding Protein (SBP) Targeting This BTS
SBP Name Highest Status Mechanism Affinity Application Details Ref
Anticalin anti-PSMA A3 Research Binder Kd: 4.6 nM Solid tumour/cancer [ICD-11: 2A00-2F9Z]
SBP Info
 		[1]
Anticalin anti-PSMA A3A5 Research Binder Kd: 2.5 nM Solid tumour/cancer [ICD-11: 2A00-2F9Z]
SBP Info
 		[1]
Anticalin anti-PSMA A3A5.1 Research Binder Kd: 0.66 nM Solid tumour/cancer [ICD-11: 2A00-2F9Z]
SBP Info
 		[1]
Anticalin anti-PSMA A3A5.7 Research Binder Kd: 0.54 nM Solid tumour/cancer [ICD-11: 2A00-2F9Z]
SBP Info
 		[1]
Bicyclic peptide anti-PSMA peptide 1 Research binder IC50: >50000 nM Research tool
SBP Info
 		[2]
BiTE Acapatamab Phase I Inhibitor N.A. Prostate cancer [ICD-11: 2C82.Z]
SBP Info
 		[3]
BiTE anti-PSMA 5D3-alphaCD3 Research binder N.A. Prostate cancer [ICD-11: 2C82.Z]
SBP Info
 		[4]
BiTE Pasotuxizumab Phase I Binder N.A. Metastatic castration-resistant prostate cancer [ICD-11: 2C82.Y]
SBP Info
 		[5], [6]
Diabody anti-PSMA cys-clone Research Binder N.A. Prostate Cancer [ICD-11: 2C82.Z]
SBP Info
 		[7]
Peptide aptamer anti-PSMA DUP-1 Research Binder N.A. Tumors [ICD-11: XH1N44]; Diagnostic reagent
SBP Info
 		[8], [9]
References
1 Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA). Protein Eng Des Sel. 2016 Mar;29(3):105-15.
2 The development of a high-affinity conformation-sensitive antibody mimetic using a biocompatible copolymer carrier (iBody). J Biol Chem. 2021 Nov;297(5):101342.
3 Amgen. Product Development Pipeline. 2021.
4 Targeting Prostate Cancer Using Bispecific T-Cell Engagers against Prostate-Specific Membrane Antigen. ACS Pharmacol Transl Sci. 2023 Oct 6;6(11):1703-1714.
5 Recent advances in the development of novel protein scaffolds based therapeutics. Int J Biol Macromol. 2017 Sep;102:630-641.
6 Amgen. Product Development Pipeline. 2019.
7 Synthesis, Positron Emission Tomography Imaging, and Therapy of Diabody Targeted Drug Lipid Nanoparticles in a Prostate Cancer Murine Model. Cancer Biother Radiopharm. 2017 Sep;32(7):247-257.
8 A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clin Cancer Res. 2005 Jan 1;11(1):139-46.
9 Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system. Cancer Lett. 2016 Dec 28;383(2):230-242.